ClinicaliQ Trial Snapshot
- A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) — Active Not Recruiting • Phase II • NCT06643481.
- Testing whether VHB937 drug slows early ALS progression compared to placebo over 40 weeks, then all patients receive active treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE). Conditions: Amyotrophic Lateral Sclerosis (ALS) Interventions: VHB937, Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 251 participants